Reports of Practical Oncology and Radiotherapy最新文献

{"title":"A prospective pilot study to evaluate the impact of palliative radiotherapy in upfront inoperable/chemo unfit patients with extrahepatic biliary tract tumors.","authors":"Divyesh Kumar, Jayanta Samanta, Harshal Mandavdhare, Santosh Irrinki, Pankaj Gupta, Parikshaa Gupta, Shikha Goyal, Divya Khosla, Rakesh Kapoor","doi":"10.5603/rpor.108662","DOIUrl":"https://doi.org/10.5603/rpor.108662","url":null,"abstract":"<p><strong>Background: </strong>Extrahepatic biliary tract cancer (BTC) group of cancers are considered as highly lethal. Patients who are unfit for definitive treatment (surgery/chemotherapy) are usually kept on best supportive care (BSC) only. Literature regarding the role of palliative radiation therapy (RT) in this patient population is limited. Thus, this study aimed to evaluate the role of palliative RT in patients with advanced-stage BTC.</p><p><strong>Materials and methods: </strong>After obtaining institutional ethics committee approval, patients who fulfilled the inclusion or exclusion criteria were included in this study. Patients were treated by palliative RT (30 Gy/10#) by 3DCRT post-PTBD insertion, if jaundice was present. Patients were assessed for response, pain, and quality of life (QoL). Results were statistically analyzed using SPSS version 22.</p><p><strong>Results: </strong>Fifteen patients were selected for analysis. The mean age of the patients was 52 years (range 41-67 years). The female-to-male ratio was 4:1. Jaundice was the primary presenting symptom in 5/15 (33.33%) of patients, whereas pain alone and in combination with jaundice was observed in 3/15 (20%) and 7/15 (46.66%), respectively. Among all assessed, 53.33% showed a partial response, 26.66% showed stable disease, and 20% showed progressive disease, while no patients had a complete response. Grade 2 toxicities were observed mainly. Statistically significant changes were seen in visual analogue scores (VAS), and QoL showed improvement post RT.</p><p><strong>Conclusions: </strong>Palliative RT seems effective in patients with advanced-stage BTC who otherwise are kept on BSC only, with minimal and manageable toxicities. Studies with a larger sample size are warranted.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"34-41"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cells therapy molecular tracking - the special focus on nuclear medicine.","authors":"Wiktoria Maria Suchorska, Witold Cholewiński, Jolanta Kunikowska, Dariusz Pawlak, Maciej Paweł Jankowski, Agata Karolina Pietrzak","doi":"10.5603/rpor.108578","DOIUrl":"https://doi.org/10.5603/rpor.108578","url":null,"abstract":"<p><strong>Background: </strong>The purpose of the study was to discuss the role of molecular imaging in stem cells (SCs) therapy and SC tracking with the special focus on nuclear medicine (NM) applications.</p><p><strong>Materials and methods: </strong>A comprehensive analysis of studies published between 2010 and 2025 focusing on the application of molecular imaging in SCs research with the special focus on NM applications.</p><p><strong>Results: </strong>Molecular imaging provides the possibility of tracking SCs <i>in vivo</i>, enabling insights into their biodistribution, viability, and therapeutic efficacy. We observed that the most of the studies discussed the use of the mesenchymal SC, neural SC and cancer SC, presenting the magnetic resonance imaging (MRI) and positron emission tomography (PET) methods as the most useful imaging tools for SCs-based therapy monitoring. However, the SCs tracking in itself is a complex issue and, more frequently than not, more than one method is required for the diagnostic protocol to be successful. Depending on the properties of the imaging technique, the different aspect - transplanted SCs biology or the treated tissue's damage and repair process - might be examined.</p><p><strong>Conclusions: </strong>Molecular imaging plays a central role in SC research, offering non-invasive and dynamic visualization of SC <i>in vivo</i> that ensures the possibility to provide the regenerative and cancer treatment with PET-CT and MRI being the most frequently mentioned in the literature and presenting different advantages in SCs-based therapy monitoring.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"142-152"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing a novel immobilization method for breast cancer radiation therapy with tissue expander.","authors":"Anna Czubowicz, Zofia Szczyrek, Marta Senkowska","doi":"10.5603/rpor.108576","DOIUrl":"https://doi.org/10.5603/rpor.108576","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"153-154"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automatic pelvic bone segmentation for radiotherapy using diagnostic imaging workstation.","authors":"Koji Kosaka, Yoshihiro Ueda, Yuji Kuroki, Hikari Minami, Shoki Inui, Masahiro Morimoto, Ryohei Sasaki","doi":"10.5603/rpor.109519","DOIUrl":"https://doi.org/10.5603/rpor.109519","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the usefulness of a diagnostic imaging workstation in streamlining procedures and improving the accuracy of contouring pelvic bones with characteristic shapes.</p><p><strong>Materials and methods: </strong>The study included 18 patients with computed tomography (CT) images of the pelvic bone undergoing radiation therapy planning. Four pelvic bone structures (ST) were created: ST_EZ1, ST_EZ3, ST_Zio, and ST_MN. ST_EZ1 and ST_EZ3 using the automatic contouring function of EZ Sketch in Monaco (Elekta Inc.), a treatment planning system (TPS). ST_EZ3 was then duplicated and manually modified to create ST_MN. The CT data were reconstructed using Ziostation2 to create pelvic bone-only data, which were then imported into the TPS to create the structure using EZ Sketch. A 2-mm inner margin was added to create ST_Zio. Each structure was compared with ST_MN and evaluated using the Hausdorff distance (HD), mean distance to agreement (MDA), Dice similarity coefficient (DSC), and Jaccard similarity coefficient (JSC).</p><p><strong>Results: </strong>A comparison of ST_EZ1, ST_EZ3, and ST_Zio with ST_MN revealed the following: average HD, 53.87, 33.14, and 16.64, respectively; average MDA, 3.70, 2.03, and 0.99, respectively; average DSC, 0.80, 0.85, and 0.91, respectively; and average JSC, 0.68, 0.74, and 0.83, respectively. The average structure creation times were 1 min 7 s for ST_EZ1, 3 min 45 s for ST_EZ3, 1 min 50 s for ST_Zio, and 33 min 5 s for ST_MN.</p><p><strong>Conclusion: </strong>Diagnostic imaging workstations are effective for pelvic bone contouring, improving both efficiency and accuracy.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"68-80"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent systemic treatment during stereotactic radiosurgery for breast cancer brain metastasis - analysis of survival outcomes and propensity score matching analysis.","authors":"Geovanne Pedro Mauro, Vinicius de Carvalho Gico, Gabriel Faria Najas, Evandro César de Souza, Eduardo Weltman, Eberval Gadelha Figueiredo, Heloisa de Andrade Carvalho, Silvia Radwanski Stuart, Leila Maria Da Róz","doi":"10.5603/rpor.109849","DOIUrl":"https://doi.org/10.5603/rpor.109849","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic radiosurgery (SRS) has a fundamental role in the treatment of breast cancer brain metastases (BCBM). Current data on the matter comes from trials with brain metastases from any histology or with limited description on survival, focusing mostly on response rate. This retrospective study will assess the impact of SRS on survival and its interaction with systemic treatment (ST).</p><p><strong>Materials and methods: </strong>Charts from January 2011 to July 2022 were retrospectively assessed to investigate the relation between SRS and concurrent ST for BCBM. Since different protocols for ST can be offered, we divided our cohort and assessed the impact of different concurrent ST, in each subtype, on oncological survival outcomes.</p><p><strong>Results: </strong>There were 208 patients, 138 met inclusion criteria. Median follow-up was 10.7 months. Median overall survival (OS), progression-free survival (PFS), survival-free from central nervous system (CNS) progression and survival-free from new neurological deficits were 12.5, 14.1, 16.2, and 16.3 months, respectively. For the whole cohort, any concurrent ST did not impact OS (p = 0.68). For hormone-positive patients, concurrent hormone therapy (HT) did not impact OS (p = 0.75). For those receiving anti-human epidermal growth factor receptor-type 2 (anti-HER-2) therapy there was no impact on OS (p = 0.47). Propensity score match analysis found that ST during SRS would reduce the chance of death by 19.4%. ST did not impact toxicities, chances of radionecrosis nor survival free of neurological symptoms.</p><p><strong>Conclusions: </strong>There has been an increase in research on the synergy between SRS and ST. In our study, this synergy was not sensible for oncological outcomes. New prospective research should focus more on survival outcomes than response rate.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"107-123"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor size as a key determinant of treatment strategy and prognosis in stereotactic body radiotherapy for pulmonary metastases: a retrospective study.","authors":"Kae Okuma, Tairo Kashihara, Koji Inaba, Kana Takahashi, Madoka Sakuramachi, Ayaka Nagao, Akane Yoshiba, Akikazu Kobori, Tongyu Gao, Shoki Nakamura, Hiroshi Igaki","doi":"10.5603/rpor.109095","DOIUrl":"https://doi.org/10.5603/rpor.109095","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic body radiotherapy (SBRT) is widely used for pulmonary metastases, but the optimal dose-fractionation strategy remains uncertain. Tumor size may critically influence both treatment selection and prognosis.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 173 metastatic lung lesions in 152 patients treated with SBRT between February 2018 and August 2023. Tumor characteristics, dose-fractionation schedules, and outcomes were assessed. Associations between tumor size, treatment choice, and prognosis were evaluated using the Kruskal-Wallis test, Kaplan-Meier method, Cox proportional hazards models, and receiver operating characteristic (ROC) analysis.</p><p><strong>Results: </strong>Median tumor size was 15 mm. Larger tumors more frequently received fractionated regimens such as 60 Gy in 10 fractions (p = 0.028). Tumor size was an independent predictor of overall survival (OS) [hazard ratio (HR) = 1.041; 95% confidence interval (CI): 1.001-1.083; p = 0.045)]. Receiver operating characteristic (ROC) analysis identified 16.75 mm as the optimal OS cutoff [area under the curve (AUC) = 0.651], with tumors above this threshold showing significantly worse OS (p = 0.009). Local control (LC) did not significantly differ by size or regimen, although larger tumors showed a non-significant LC decline. Primary tumor histology was not associated with OS or LC. Grade ≥ 2 radiation pneumonitis occurred in 5.3% of cases.</p><p><strong>Conclusions: </strong>Tumor size is a decisive factor shaping both dose-fractionation and survival in SBRT for pulmonary metastases. Larger tumors tend to receive more fractionated, lower BED regimens, potentially compromising survival. Prospective trials incorporating tumor size-based stratification and BED optimization are warranted to improve outcomes.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"88-95"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of sensitivity of low-cost fluorescein as an alternative to radiocolloid for sentinel lymph node biopsy in breast carcinoma.","authors":"Prashant Gupta, Varun Kumar Agarwal, Anoop Kumar Varshney","doi":"10.5603/rpor.109091","DOIUrl":"https://doi.org/10.5603/rpor.109091","url":null,"abstract":"<p><strong>Background: </strong>Sentinel lymph node biopsy (SLNB) is important in the treatment and staging of early-stage breast carcinoma. Traditional methods, including blue dyes and radiocolloids, are limited by high cost, radiation safety concerns, and reliance on nuclear medicine centers. Low-cost fluorescent dye, fluorescein, has been suggested as a potential alternative due to its safety, ease of visualization, and low cost. This study aimed to find the sensitivity of fluorescein as an alternative to radiocolloid in SLNB for breast carcinoma.</p><p><strong>Materials and methods: </strong>A prospective observational study was done at a tertiary care teaching hospital in 50 female patients of early-stage breast carcinoma. Intraoperative injection of fluorescein and visualization with ultraviolet (UV) light were done. Sentinel nodes were detected with a hand-held UV light source.</p><p><strong>Results: </strong>Fluorescein detected sentinel nodes in 96% of patients. Fluorescein had a sensitivity of 96%, specificity of 98%, and 4.2% false-negative rate (FNR). Negative predictive value (NPV) was 98.5%. No significant adverse effects were noted.</p><p><strong>Conclusions: </strong>Fluorescein is a safe, cost-effective, and efficient replacement for radiocolloid in SLNB in breast cancer. It provides outstanding identification rates, sensitivity, and specificity and can be utilized to the best in low-resource settings. Multicenter trials are required to confirm these findings and promote more widespread adoption of fluorescein-based SLNB in clinical care.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"50-58"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoral stent for head and neck radiotherapy using 3D technology: an integrative review.","authors":"Gabrielly Maria Argolo Acioly, Matheus Henrique Alves de Lima, Celina Wanderley de Abreu","doi":"10.5603/rpor.109097","DOIUrl":"10.5603/rpor.109097","url":null,"abstract":"<p><p>The aim of the study was to conduct an integrative review on intraoral stents for head and neck radiotherapy using 3D technology. For data collection, the words were used: \"intraoral stent\", \"oral cancer\" and \"3D\", with their combination performed using the Boolean operator AND. Only articles in English were selected from the PubMed and LILACS databases. The search process was conducted between August and October 2024. Eight articles were found, of which seven met the established inclusion criteria. The articles demonstrate that the use of 3D technology optimizes the fabrication time of intraoral stents, directs isodose distribution to the treated area while preserving adjacent healthy tissues, and reduces side effects during the irradiation period. Evident advances in the literature regarding the innovation in the production of intraoral stents, such as 3D printing, have demonstrated effectiveness and benefits in this treatment modality.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"857-862"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to tailor the radiotherapy after radical prostatectomy in the modern era of molecular imaging, genomic testing, and technology development?","authors":"Piotr Milecki","doi":"10.5603/rpor.110163","DOIUrl":"10.5603/rpor.110163","url":null,"abstract":"<p><p>In recent years, we have observed a significant increase in the number of radical prostatectomies (RP) performed in patients at very high risk of prostate cancer. This group of patients is very heterogeneous due to the presence of multiple risk factors for recurrence, which makes decisions regarding the use of salvage radiotherapy (RT) very challenging. On the one hand, there is a subgroup of patients who can only be observed. For a more advanced subgroup of patients postoperative RT alone is effective treatment. For patients with very aggressive biology characteristics RT should be combined with systemic therapy. Unfortunately, we still do not have ideal tools to precisely assign individual patients to these subgroups. Clinicopathological factors are very helpful in this regard. So, introduction of modern molecular diagnostics, i.e., positron emission tomography (PET) using a radiotracer that binds to prostate-specific membrane antigen (PET-PSMA), allowed for a change in the general strategy for salvage RT. Information from PET scans included in the RT plan allow for increasing the effectiveness of RT. Another method for personalizing RT planning is the use of genomic testing. To date, the most clinically validated method allows for the identification of a subgroup of patients in whom combined treatment [androgen deprivation therapy (ADT) + RT] yields the greatest clinical benefits. Improvement in RT outcomes is associated with the introduction of technologically advanced RT methods, such as adaptive RT (ART), which provides the opportunity for a precise delivery of dose to a tumour bed. Another very promising development involves new predictive tests for RT which are based on genomic analysis of cancer tissue.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"828-839"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late cardiac effects in patients with left breast cancer treated with hypofractionated radiotherapy.","authors":"Budhi Singh Yadav, Ashwani Sood, Divya Dahiya","doi":"10.5603/rpor.109183","DOIUrl":"10.5603/rpor.109183","url":null,"abstract":"<p><strong>Background: </strong>In this study we aimed to analyse the late cardiac effects in patients with left sided breast cancer treated with hypofractionated radiotherapy.</p><p><strong>Materials and methods: </strong>Between January 1990 to December 2005, patients treated for left side breast cancer who had received radiotherapy at least 10 years earlier were included in this study. Radiotherapy dose was 35-40 Gy/15-16#/3 weeks. These patients underwent echocardiography, stress myocardial perfusion scintigraphy (MPS) to look for any myocardial perfusion defect (MPD). MPD extent was defined as not significant, mild, moderate and large if it was < 5%, 5-10%, > 10-20% and > 20%, whereas severity was defined as mild moderate and severe, respectively.</p><p><strong>Results: </strong>A total of 87 patients underwent stress myoperfusion scan (MPS). MPDs were observed in 31 (36%) patients. MPDs were not significant, mild and moderate in 5 (6%), 25 (28%) and 1 (1%) patients, respectively. In majority of patients [30 (97%)], MPDs were observed in the apex and apical anterior segment of the left ventricle myocardium. MPD intensity was mild, mild to moderate and moderate in 21 (68%), 4 (13%) and 6 (19%) patients, respectively. MPDs were reversible, partially reversible, minimally reversible and fixed in 22 (71%), 3 (10%) 1 (3%) and 5 (16%) patients, respectively. Central lung distance (CLD) ≥ 2.5 cm was a significant factor for MPDs (p = 0.027). Left ventricular ejection fraction deterioration was observed in 2 (6%) patients only. Coronary events occurred in 4 (4.5%) patients.</p><p><strong>Conclusions: </strong>In patients with left sided breast radiotherapy majority of MPDs were mild. Moderate and fixed MPDs were associated with CLD ≥ 2.5 cm. Left ventricular functional deterioration was observed in few patients only.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"781-788"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}